Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolar Disorder
ConditionBipolar Disorder
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorMclean Hospital
About this trial
Preliminary data have suggested that cannabidiol (CBD) may have a number of clinical benefits, including anti-anxiety and antidepressant properties. This study is a pilot open-label clinical trial assessing a custom-formulated high-CBD product over the course of 4 weeks in patients with bipolar disorder who experience anxiety.
Eligibility criteria
Qualifiers
Provides informed consent
Between the ages of 18-65
Fluent in English
Meets DSM-5 criteria for bipolar disorder (type I or II)
Disqualifiers
Not fluent in English
Estimated IQ <75
Current substance use disorder, current eating disorder, current or past psychotic disorder (e.g. schizophrenia, schizoaffective disorder)
Endorsement of suicidality
Trial design
Treatments tested in this trial
- Cannabidiol
Treatment groups
25 Participants
are divided into 1 treatment groupLocations
1McLean Hospital02478, BelmontMassachusetts, United States
Sponsors and collaborators
Mclean Hospital
Lead sponsor
Source ClinicalTrials.gov